HLA Screening and Testosterone Therapy for Metal Implant Reactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively identify and manage adverse reactions to metal debris from joint replacements, such as ALVAL, leading to unexplained pain and tissue destruction in patients with metal implants, and there is a need for improved screening and therapeutic interventions to prevent or ameliorate these reactions.
Innovation Solution
A method involving genetic screening using HLA genotypes and enzyme-linked immunosorbent assay (ELISA) to detect markers associated with adverse responses, combined with the use of testosterone or its precursors to interfere with the MHC-mediated immune response, to predict and treat adverse reactions to metal debris.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If metal on metal hip replacements are used to increase stability and reduce wear, then implant durability is improved, but adverse immune responses to metal debris occur leading to tissue destruction
Solution Approach 1:
The patent performs HLA genotype screening and ELISA testing before implantation to identify patients at high risk of adverse reactions to metal debris. By detecting specific HLA alleles (HLA-DRB1*01, *04, *10, HLA-DQA1*05:01/DQB1*02:01, HLA-DRB1*07, HLA-DRB1*0103, HLA-DRB3*0301) and anti-HLA antibodies in advance, the system enables preventive decision-making regarding implant selection, thereby avoiding the harmful immune response while maintaining implant durability for suitable candidates
Solution Approach 2:
The patent introduces therapeutic compounds that interfere with MHC-mediated immune responses as intermediaries between the metal implant and the patient's immune system. These compounds block the presentation of metal debris antigens by MHC molecules, preventing the activation of T-cells and subsequent adverse immune responses, thereby allowing metal on metal implants to maintain their durability benefits without triggering ALVAL reactions
2Measurement precision
If HLA screening and ELISA testing are performed to identify at-risk patients, then accuracy in predicting adverse responses is improved, but complexity of the screening process increases
Solution Approach 1:
The patent divides the screening process into distinct modular components: HLA genotype testing (detecting specific allele combinations), ELISA testing for anti-HLA antibodies, and separate therapeutic intervention pathways. This segmentation allows each test to be performed independently with established laboratory methods, making the overall complex process manageable and scalable while maintaining high predictive accuracy through the combination of multiple targeted assays
3Reliability
If compounds interfering with MHC-mediated immune response are used to prevent ALVAL, then effectiveness in preventing adverse reactions is improved, but understanding of the underlying mechanisms remains incomplete
Solution Approach 1:
The patent employs a feedback approach by monitoring patients' HLA genotypes, anti-HLA antibody levels, and clinical outcomes to refine the understanding of MHC-mediated immune responses to metal debris. The screening and treatment protocols generate data on which HLA allele combinations and antibody profiles are most strongly associated with adverse reactions, and how therapeutic compounds affect these parameters, thereby progressively building mechanistic knowledge while maintaining reliable prevention and treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for personalized joint replacement strategies by identifying at-risk patients and potentially reducing the risk of ALVAL and macrophage-dominated responses, thereby improving patient outcomes and understanding of immune-mediated conditions.
Implementation Method 1
the use of testosterone or its precursors to interfere with the MHC-mediated immune response
Data Source
AI summary
Methods of screening a subject to determine whether or not they are at risk of having an adverse reaction to metal debris (ARMD), also known as adverse local tissue reaction (ALTR), methods of screening compounds for use in preventing or ameliorating such an adverse response and compounds for use in treating a subject.